parallel randomized trial
S003039
Type 2 diabetes (adults)S003039
Design
Conduct and analysis
Arms
| Arm | Treatment | Background | Randomized | Analyzed | Completed treatment |
|---|---|---|---|---|---|
| A1 | dulaglutide Switch to dulaglutide | liraglutide stopped; other glucose lowering drugs and insulin unchanged; lifestyle: standard | 11 | 11 | |
| A2 | liraglutide Continue liraglutide | other glucose lowering drugs and insulin unchanged; lifestyle: standard | 11 | 11 |
Baseline characteristics
As printed in the trial reports or registry, per arm or for the whole trial.
| Characteristic | Statistic | Switch to dulaglutide A1 | Continue liraglutide A2 |
|---|---|---|---|
| age | mean (years) | 69.2 | 67.8 |
| age | sd (years) | 9.1 | 9.5 |
| bmi | mean (kg/m2) | 26.7 | 25.9 |
| bmi | sd (kg/m2) | 4.4 | 3.6 |
| diabetes duration | mean (years) | 14.5 | 13.7 |
| diabetes duration | sd (years) | 8.9 | 8.2 |
| egfr | mean (mL/min/1.73 m2) | 71.5 | 76.6 |
| egfr | sd (mL/min/1.73 m2) | 18.0 | 19.2 |
| established cvd | n | 5 | 2 |
| established cvd | percent | 45.5 | 18.2 |
| hba1c | mean (percent) | 7.1 | 7.2 |
| hba1c | sd (percent) | 0.5 | 0.5 |
| insulin use | n | 3 | 8 |
| insulin use | percent | 27.3 | 72.7 |
| metformin use | n | 5 | 5 |
| metformin use | percent | 45.5 | 45.5 |
| other agi use | n | 5 | 1 |
| other agi use | percent | 45.5 | 9.1 |
| other glinide use | n | 0 | 1 |
| other glinide use | percent | 0.0 | 9.1 |
| other male | n | 9 | 4 |
| other male | percent | 81.8 | 36.4 |
| other sulfonylurea use | n | 1 | 0 |
| other sulfonylurea use | percent | 9.1 | 0.0 |
| other thiazolidinedione use | n | 1 | 1 |
| other thiazolidinedione use | percent | 9.1 | 9.1 |
| sbp | mean (mmHg) | 137.5 | 138.5 |
| sbp | sd (mmHg) | 17.5 | 19.1 |
| sglt2i use | n | 1 | 2 |
| sglt2i use | percent | 9.1 | 18.2 |
| weight | mean (kg) | 68.3 | 63.4 |
| weight | sd (kg) | 13.4 | 12.9 |
Analyses this trial contributes to
Results
8 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
HbA1c change (2 lines; O01)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| 24 | A1 | final | 7.1 percent | 0.6 | 11 | not stated; completers; R0019432:Table 2 | |
| 24 | A2 | final | 7.6 percent | 0.9 | 11 | not stated; completers; R0019432:Table 2 |
Body weight change in kilograms (diabetes) (2 lines; O02)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| 24 | A1 | final | 69.1 kg | 14.0 | 11 | not stated; completers; R0019432:Table 2 | |
| 24 | A2 | final | 64.4 kg | 13.8 | 11 | not stated; completers; R0019432:Table 2 |
Systolic blood pressure change (2 lines; O05)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| 24 | A1 | final | 136.8 mmHg | 20.2 | 11 | not stated; completers; R0019432:Table 2 | |
| 24 | A2 | final | 131.6 mmHg | 21.1 | 11 | not stated; completers; R0019432:Table 2 |
Health related quality of life total score (any instrument) (2 lines; O24C)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| 24 | A1 | final | 30.00 points | 5.60 | 11 | not stated; completers; R0019432:Table 3 | |
| 24 | A2 | final | 26.36 points | 3.98 | 11 | not stated; completers; R0019432:Table 3 |